# Loop Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/loop-genomics

- Industry: Biotechnology
- Headquarters: San Jose, US
- Website: www.loopgenomics.com
- Total disclosed funding: $8M
- Latest round: Series A (Nov 1, 2018)
- Investors on record: 6

## About

Loop Genomics provides advanced genomic sequencing solutions, specializing in innovative technologies that enable efficient and high-quality DNA and RNA analysis for research and clinical applications.Loop Genomics was founded in 2015 in San Jose, US, and focuses on genomic sequencing technologies that facilitate DNA and RNA analysis. The company has not undergone any significant pivots since its inception. Tuval Ben-Yehezkel is the CEO and founder, with a background that includes experience in other ventures. Loop Genomics has raised a total of USD 8.00 mn in its Series A funding round led by Khosla Ventures, securing investment from notable firms including DN Capital, Fusion Fund, Wilson Sonsini Goodrich & Rosati, Wisemont Capital, and Y Combinator, with its most recent deal dated 2022-02-08.Loop Genomics specializes in providing advanced genomic sequencing solutions that streamline laboratory workflows. Its systems eliminate the need for library preparation, allowing researchers to conduct rapid and high-quality genomic analyses. The company's products cater primarily to academic institutions, research laboratories, and biotechnology firms, enhancing their capabilities in genomic research across North America, Europe, and Asia.Loop Genomics generates revenue primarily through the sale of its genomic sequencing systems and associated reagents. The company targets B2B transactions with research institutions and biotech companies, focusing on integrating its technologies into existing laboratory processes. Its pricing strategy aims to deliver accessible solutions for institutions looking to leverage advanced genomic analysis without incurring excessive costs.Loop Genomics plans to leverage its recent acquisition by Element Biosciences to enhance its product offerings, particularly focusing on dual short and long-read genomic applications. The acquisition will allow for the integration of Loop Genomics' technologies into Element's existing platform, aimed at broadening market reach. The funding from its Series A round will support the development of new products designed for simultaneous DNA and RNA sequencing applications. Expansion plans target international markets in Europe and Asia by 2024, positioning the company to capitalize on the growing demand for genomic research tools.

## Funding rounds

- Series A, Nov 1, 2018, $8M — Khosla Ventures, DN Capital, Y Combinator, Wilson Sonsini Goodrich & Rosati, Fusion Fund, Wisemont Capital

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A
- DN Capital (https://capitalatlas.ai/funds/dn-capital) — Series A
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Series A
- Wilson Sonsini Goodrich & Rosati — Series A
- Fusion Fund (https://capitalatlas.ai/funds/fusion-fund) — Series A
- Wisemont Capital (https://capitalatlas.ai/funds/wisemont-capital) — Series A